Telehealth prescribing rules frequently distinguish between a new patient and one who already has an established relationship with a clinician or practice. That distinction can affect what kind of visit is required before a prescription is written, and it becomes especially important when the medication in question is a controlled substance.
Why the distinction matters
For an established patient, many state boards and telehealth statutes treat a video or even audio-only follow-up as sufficient to support a prescribing decision, since the clinician already has a documented history, prior exam findings, and an existing care plan. A new patient relationship, by contrast, often triggers additional expectations around the type of exam, the documentation created during the encounter, and in some states a preference or requirement for real-time audio-video rather than a written questionnaire alone.
Controlled substances add complexity
When the prescription involves a controlled substance, the new-versus-established distinction tends to matter even more. Federal framework changes around telehealth prescribing of controlled substances have been evolving, and DEA registration rules interact with state-level practice-of-medicine requirements. Some states have historically required an initial in-person exam before a controlled substance could be prescribed via telehealth, while others have permitted exceptions during declared public health emergencies or through specific telehealth provisions. Because federal and state rules can each impose their own conditions, the more restrictive requirement generally governs in practice.
The gap between prescribing for a new patient and an established one is often the difference between a straightforward telehealth visit and one that requires extra documentation or an in-person step.
What practices tend to track
Practices operating across multiple states typically track which states require an initial in-person or synchronous video visit before a new patient can be prescribed a controlled substance, which states allow full telehealth-only relationships, and which states have carved out exceptions for specific specialties such as psychiatry or opioid use disorder treatment. These rules can change as state legislatures and boards revisit emergency-era telehealth flexibilities, so a rule that applied last year may no longer reflect current guidance.
A note on documentation
Regardless of whether a patient is new or established, most boards expect the encounter to be documented in a way that supports the prescribing decision — including the modality used, the information gathered, and the clinical reasoning. This documentation standard tends to apply consistently, even as the underlying visit-type requirements vary by state.
Because these distinctions shift over time and differ by specialty and substance schedule, they are worth revisiting periodically. Requirements vary by state and change over time — always confirm current requirements directly with the relevant state board or agency before making a compliance decision.